MTVAMetaVia Inc.
MTVA
MetaVia Inc.14,727
Mkt Cap
$7.33MVolume
69,138.0052W High
$19.0352W Low
$1.17PE Ratio
-0.16MTVA Fundamentals
Price
$1.44Prev Close
$1.44Open
$1.4550D MA
$1.46Beta
0.98Avg. Volume
143,239.88EPS (Annual)
-$7.35P/B
0.62Rev/Employee
$0.00$4.80
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity PR Newswire CAMBRIDGE...
PR Newswire·22d ago
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update PR Newswire CAMBRIDGE, Mass., March 26, 2026 48 mg Phase 1 Data Demonstrate Potential Best-in-Class Profile for DA-1726 with 9.1% Weight Loss...
PR Newswire·1mo ago
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and...
PR Newswire·1mo ago
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035 MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and...
PR Newswire·2mo ago
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences...
PR Newswire·2mo ago
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference PR...
PR Newswire·2mo ago
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041 MetaVia Builds Comprehensive Global Patent Protection...
PR Newswire·3mo ago
What Does the Market Think About MetaVia Inc?
read more...
Benzinga·3mo ago
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering...
PR Newswire·4mo ago
MetaVia Stock Slides After Pricing Public Offering
(RTTNews) - MetaVia Inc. (MTVA) shares traded at $3.4050, down 39.03% or $2.18 lower, after the company announced the pricing of an $8.1 million underwritten public offering...
Nasdaq News: Markets·4mo ago
<
1
2
...
>